Charles River Labs Intl Aktie
Charles River Labs Intl Aktie
Was spricht für und gegen Charles River Labs Intl in den nächsten Jahren?
Pro
Kontra
Rendite von Charles River Labs Intl im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Charles River Labs Intl | -0,05 % | 1,15 % | -6,77 % | 26,92 % | 2,82 % | -22,34 % | - |
Ironwood Pharmaceuticals | 0,68 % | 2,76 % | 2,05 % | -22,80 % | -26,96 % | -18,13 % | - |
Sage Therapeutics Inc. | 0,04 % | -11,65 % | -24,64 % | -75,36 % | -42,35 % | -80,72 % | - |
Novocure Ltd | 3,29 % | 30,07 % | 14,28 % | -76,33 % | 4,55 % | -90,57 % | - |
Kommentare
News
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing